...
首页> 外文期刊>Annals of surgical oncology >Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma
【24h】

Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma

机译:膀胱术后膀胱术后膀胱切除术后膀胱切除术治疗原发性上部尿路上皮癌的膀胱切除术后的独立预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Few studies have described the clinical courses and outcomes in the bladder after treatment of intravesical recurrence after radical nephroureterectomy (RNU) in patients with primary upper tract urothelial carcinoma (UTUC). We investigated the indicators for predicting subsequent bladder outcomes after treatment of intravesical recurrence after RNU. Methods. A total of 241 patients with primary UTUC (pTa-4N0M0) who experienced intravesical recurrence after RNU were included. Of these patients, 101 (41.9 %) underwent Bacillus Calmette-Guérin treatments, whereas 49 (20.3 %) underwent intravesical chemotherapy. The median follow-up period after initial transurethral resection of the bladder tumor was 33 months. Relationships with bladder outcomes were analyzed by using multivariable analysis. Results. Ninety-six patients experienced intravesical recurrence, and bladder progression was observed in 13. Cumulative incidence rates of intravesical recurrence at 1 and 5 years after treatment of the first intravesical recurrence were 31.0 and 48.4 %, whereas those of bladder progression at 1 and 5 years thereafter were 2.4 and 8.0 %. Multivariate analysis showed that the number of recurrent tumors and pT1 tumors at the time of the first intravesical relapse were independent risk factors for subsequent intravesical recurrence. With respect to bladder progression, multivariate analysis showed that pT1 tumors, the appearance of concomitant carcinoma-in situ at the time of the first intravesical relapse, and the absence of the Bacillus Calmette-Guérin treatment were independent risk factors. Conclusions. This retrospective study presents a detailed picture of further bladder outcomes after intravesical recurrence after RNU in primary UTUC patients. The results may assist physicians to develop a more rational protocol in bladder surveillance.
机译:背景。在患有原发性上部尿路上皮癌(UTUC)后自由基肾脏表切除术(RNU)后膀胱术复发的膀胱内的临床疗法和结果描述了膀胱术。我们调查了在治疗RNU后治疗膀胱内复发后预测后续膀胱结果的指标。方法。包括在RNU后经历膀胱内复发的初级UTUC(PTA-4N0M0)的241名患者。在这些患者中,101例(41.9%)接受了芽孢杆菌的芽孢杆菌治疗方法,而49(20.3%)接受膀胱内化疗。膀胱肿瘤初始经尿道切除后的中位随访时间为33个月。通过使用多变量分析来分析与膀胱结果的关系。结果。九十六名患者经历了膀胱内复发,并观察到膀胱进展于13.治疗第一次膀胱术复发后1和5年的累积发病率为31.0和48.4%,而1和5年的膀胱进展的膀胱进展此后为2.4和8.0%。多变量分析表明,在第一次膀胱内复发时经常性肿瘤和PT1肿瘤的数量是随后膀胱内复发的独立危险因素。关于膀胱进展,多变量分析表明,PT1肿瘤,在第一次脑内复发时伴随癌的外观,并且没有芽孢杆菌秃鹰植物治疗是独立的危险因素。结论。该回顾性研究提出了在初级尾部患者RNU后膀胱内复发后进一步膀胱结果的详细情况。结果可以帮助医生在膀胱监测中发挥更合理的协议。

著录项

  • 来源
    《Annals of surgical oncology》 |2014年第9期|共8页
  • 作者单位

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Saitama City Hospital Saitama Japan Department of Urology Inagi City;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan Department of Urology;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Urology International Medical Center-Comprehensive Cancer Center Saitama Medical;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Urology National Hospital Organization Saitama Hospital Saitama Japan;

    Department of Urology Keio University School of Medicine Tokyo Japan;

    Department of Diagnostic Radiology Keio University School of Medicine Tokyo Japan;

    Department of Urology National Hospital Organization Tochigi Hospital Tochigi Japan;

    Department of Urology Saiseikai Yokohamashi Tobu Hospital Kanagawa Japan;

    Department of Urology Keio University School of Medicine Tokyo Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 外科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号